Reduction of Airway Hyperresponsiveness by KWLL in Dermatophagoides-pteronyssinus-Challenged Mice

Overview

Journal Evid Based Complement Alternat Med

Specialty Rehabilitation Medicine

Date 2013 Mar 28

PMID 23533467

Authors

Chih-Che Lin

Shulhn-Der Wang

Li-Jen Lin

Hong-Jye Hong

Chin-Jen Wu

Chung-Jen Chiang

Yun-Peng Chao

Shung-Te Kao

Affiliations

Soon will be listed here.

Abstract

Urine therapy has been commonly practiced in ancient civilizations including those of India, China, and Greece. The traditional Chinese medicine KWLL, the precipitation of human urine, has been used in China to alleviate the symptoms of asthma for thousands of years. However, the mechanism of action by which KWLL exerts its immunotherapy is unclear. This study attempted to elucidate the pharmacology of KWLL in mice that had been challenged recurrently by Dermatophagoides pteronyssinus (Der p). BALB/c mice were orally administered KWLL (1 g/kg) before an intratracheal (i.t.) challenge of Der p. Allergic airway inflammation and remodeling were provoked by repetitive Der p (50 μ g/mice) challenges six times at 1 wk intervals. Airway hypersensitivity, histological lung characteristics, and the expression profiles of cytokines and various genes were assessed. KWLL reduced Der p-induced airway hyperresponsiveness and inhibited eosinophil infiltration by downregulating the protein expression of IL-5 in bronchoalveolar lavage fluid (BALF). It also inhibited neutrophil recruitment by downregulating IL-17A in BALF. KWLL effectively diminished inflammatory cells, goblet cell hyperplasia, and mRNA expression of IL-6 and IL-17A in the lung. The reduction by KWLL of airway inflammatory and hyperresponsiveness in allergic asthmatic mice was mediated via immunomodulation of IL-5, IL-6, and IL-17A.

References

Li X, Brown L . Efficacy and mechanisms of action of traditional Chinese medicines for treating asthma and allergy. J Allergy Clin Immunol. 2009; 123(2):297-306. PMC: 2748395. DOI: 10.1016/j.jaci.2008.12.026. View

Schnyder-Candrian S, Togbe D, Couillin I, Mercier I, Brombacher F, Quesniaux V . Interleukin-17 is a negative regulator of established allergic asthma. J Exp Med. 2006; 203(12):2715-25. PMC: 2118159. DOI: 10.1084/jem.20061401. View

Rothenberg M, Hogan S . The eosinophil. Annu Rev Immunol. 2006; 24:147-74. DOI: 10.1146/annurev.immunol.24.021605.090720. View

Galli S, Tsai M, Piliponsky A . The development of allergic inflammation. Nature. 2008; 454(7203):445-54. PMC: 3573758. DOI: 10.1038/nature07204. View

Foster P, Mould A, Yang M, Mackenzie J, Mattes J, Hogan S . Elemental signals regulating eosinophil accumulation in the lung. Immunol Rev. 2001; 179:173-81. DOI: 10.1034/j.1600-065x.2001.790117.x. View

Molet S, Hamid Q, Davoine F, Nutku E, Taha R, Page N . IL-17 is increased in asthmatic airways and induces human bronchial fibroblasts to produce cytokines. J Allergy Clin Immunol. 2001; 108(3):430-8. DOI: 10.1067/mai.2001.117929. View

Park S, Lee Y . Interleukin-17 regulation: an attractive therapeutic approach for asthma. Respir Res. 2010; 11:78. PMC: 2894770. DOI: 10.1186/1465-9921-11-78. View

Hall I . The beta-agonist controversy revisited. Lancet. 2004; 363(9404):183-4. DOI: 10.1016/S0140-6736(03)15369-X. View

Medoff B, Thomas S, Luster A . T cell trafficking in allergic asthma: the ins and outs. Annu Rev Immunol. 2008; 26:205-32. DOI: 10.1146/annurev.immunol.26.021607.090312. View

10.

Lin L, Lin C, Wang S, Chao Y, Kao S . The Immunomodulatory Effect of You-Gui-Wan on Dermatogoides-pteronyssinus-Induced Asthma. Evid Based Complement Alternat Med. 2012; 2012:476060. PMC: 3363355. DOI: 10.1155/2012/476060. View

11.

Sheth A, Reddymasu S, Jackson R . Worsening of asthma with systemic corticosteroids. A case report and review of literature. J Gen Intern Med. 2006; 21(2):C11-3. PMC: 1484654. DOI: 10.1111/j.1525-1497.2005.00290.x. View

12.

Linden A . Interleukin-17 and airway remodelling. Pulm Pharmacol Ther. 2005; 19(1):47-50. DOI: 10.1016/j.pupt.2005.02.004. View

13.

Verstraelen S, Bloemen K, Nelissen I, Witters H, Schoeters G, van den Heuvel R . Cell types involved in allergic asthma and their use in in vitro models to assess respiratory sensitization. Toxicol In Vitro. 2008; 22(6):1419-31. DOI: 10.1016/j.tiv.2008.05.008. View

14.

Hammad H, Lambrecht B . Dendritic cells and airway epithelial cells at the interface between innate and adaptive immune responses. Allergy. 2011; 66(5):579-87. DOI: 10.1111/j.1398-9995.2010.02528.x. View

15.

Kearley J, Robinson D, Lloyd C . CD4+CD25+ regulatory T cells reverse established allergic airway inflammation and prevent airway remodeling. J Allergy Clin Immunol. 2008; 122(3):617-24.e6. PMC: 3389733. DOI: 10.1016/j.jaci.2008.05.048. View

16.

Saw S, Kale S, Arora N . Serine protease inhibitor attenuates ovalbumin induced inflammation in mouse model of allergic airway disease. PLoS One. 2012; 7(7):e41107. PMC: 3400607. DOI: 10.1371/journal.pone.0041107. View

17.

Li X . Complementary and alternative medicine in pediatric allergic disorders. Curr Opin Allergy Clin Immunol. 2009; 9(2):161-7. PMC: 2770271. DOI: 10.1097/ACI.0b013e328329226f. View

18.

Barczyk A, Pierzchala W, Sozanska E . Interleukin-17 in sputum correlates with airway hyperresponsiveness to methacholine. Respir Med. 2003; 97(6):726-33. DOI: 10.1053/rmed.2003.1507. View

19.

Slader C, Reddel H, Jenkins C, Armour C, Bosnic-Anticevich S . Complementary and alternative medicine use in asthma: who is using what?. Respirology. 2006; 11(4):373-87. DOI: 10.1111/j.1440-1843.2006.00861.x. View

20.

Kudo M, Melton A, Chen C, Engler M, Huang K, Ren X . IL-17A produced by αβ T cells drives airway hyper-responsiveness in mice and enhances mouse and human airway smooth muscle contraction. Nat Med. 2012; 18(4):547-54. PMC: 3321096. DOI: 10.1038/nm.2684. View